Response to Letter to the editor

We appreciate the opportunity to respond to the points raised by Dr. Shoffner concerning the interpretation of the data from our trial, "Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial." This article is protected by copyright. All rights reserved.